SUN-348 Cabozantinib in Advanced Adrenocortical Carcinoma: Rationale and Protocol of Two Phase II Clinical Trials

BACKGROUND: Median overall survival (OS) in advanced adrenocortical (ACC) is only 12-15 months. Mitotane and chemotherapy are the backbones of current treatment but prolonged disease stabilization is rare. Cabozantinib (CABO) is an oral multi-kinase inhibitor (MKI) of c-MET, VEGFR2, AXL, and RET. OB...

Descripción completa

Detalles Bibliográficos
Autores principales: Kroiss, Matthias, Goebeler, Maria-Elisabeth, Jimenez, Camilo, Malzahn, Uwe, Fassnacht, Martin, Habra, Mouhammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Adrenal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553301/
http://dx.doi.org/10.1210/js.2019-SUN-348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553301/
http://dx.doi.org/10.1210/js.2019-SUN-348

Ejemplares similares